Tilt Investment Management Holdings PBC Sells 1,627 Shares of Boston Scientific Co. (NYSE:BSX)

Tilt Investment Management Holdings PBC lowered its stake in Boston Scientific Co. (NYSE:BSX) by 21.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,950 shares of the medical equipment provider’s stock after selling 1,627 shares during the period. Tilt Investment Management Holdings PBC’s holdings in Boston Scientific were worth $344,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. International Assets Investment Management LLC acquired a new position in shares of Boston Scientific during the first quarter worth approximately $54,000. Acadian Asset Management LLC bought a new position in Boston Scientific during the first quarter worth $35,000. Prudential PLC acquired a new position in Boston Scientific during the 1st quarter valued at $1,076,000. Cetera Investment Advisers boosted its holdings in Boston Scientific by 24.0% in the 1st quarter. Cetera Investment Advisers now owns 28,793 shares of the medical equipment provider’s stock valued at $1,275,000 after purchasing an additional 5,581 shares during the period. Finally, Sequoia Financial Advisors LLC acquired a new stake in Boston Scientific in the 1st quarter worth $230,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total transaction of $455,210.00. Following the transaction, the director now owns 41,374 shares of the company’s stock, valued at $2,690,551.22. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the sale, the director now owns 41,374 shares of the company’s stock, valued at approximately $2,690,551.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Daniel J. Brennan sold 13,662 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the completion of the transaction, the chief financial officer now owns 271,542 shares in the company, valued at $17,883,756.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,979 shares of company stock worth $3,418,529. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BSX. TD Cowen upped their price objective on shares of Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research report on Thursday, March 7th. BTIG Research reissued a “buy” rating and set a $64.00 price target on shares of Boston Scientific in a research note on Friday, December 29th. Raymond James lifted their target price on shares of Boston Scientific from $67.00 to $73.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 1st. Royal Bank of Canada boosted their price objective on shares of Boston Scientific from $70.00 to $78.00 and gave the company an “outperform” rating in a report on Monday. Finally, Wells Fargo & Company boosted their price target on shares of Boston Scientific from $70.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Two research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $68.50.

Boston Scientific Stock Down 1.0 %

Shares of Boston Scientific stock traded down $0.71 on Thursday, reaching $67.25. 3,918,760 shares of the company were exchanged, compared to its average volume of 6,340,353. Boston Scientific Co. has a one year low of $48.35 and a one year high of $69.21. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $67.17 and a 200 day moving average of $59.68. The company has a market capitalization of $98.66 billion, a price-to-earnings ratio of 63.51, a PEG ratio of 2.39 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. During the same period in the prior year, the firm posted $0.45 earnings per share. On average, equities research analysts forecast that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.